Clinical Trial Update: Lipoic Acid and Omega-3 Fatty Acids for Cognitive Impairment in Multiple Sclerosis [Phase 1, Phase 2]

View source ↗

Summary

This is a completed Phase 1/Phase 2 clinical trial evaluating alpha-lipoic acid and omega-3 fatty acids for cognitive impairment in multiple sclerosis; results …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• Alpha Lipoic Acid (alpha-lipoic acid)
• Omega-3 fatty acids (omega-3 fatty acids)

Snippet

Sponsor: Oregon Health and Science University | Conditions: Multiple Sclerosis, Cognition | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2017-05-03